{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:36:05Z","timestamp":1781220965844,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018317","name":"School of Medicine, Virginia Commonwealth University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-023-14407-1","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:13:15Z","timestamp":1697451195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Luminal A Versus B After Choosing Wisely: Does Lymph Node Surgery Affect Oncologic Outcomes?"],"prefix":"10.1245","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8316-0076","authenticated-orcid":false,"given":"Cynthia","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandace P.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"14407_CR1","unstructured":"U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999-2019). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. https:\/\/www.cdc.gov\/cancer\/dataviz. Published in November 2022. Accessed February 2021."},{"key":"14407_CR2","unstructured":"Breast Cancer Facts & Figures 2019\u20132020. Atlanta: American Cancer Society; 2019. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2019-2020.pdf. Published in 2020. Accessed February 2021."},{"issue":"Suppl 2","key":"14407_CR3","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26\u201335. https:\/\/doi.org\/10.1016\/j.breast.2015.07.008.","journal-title":"Breast"},{"key":"14407_CR4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2531-z","author":"AS Caudle","year":"2012","unstructured":"Caudle AS, Hunt KK, Tucker SL, et al. American college of surgeons oncology group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012. https:\/\/doi.org\/10.1245\/s10434-012-2531-z.","journal-title":"Ann Surg Oncol."},{"key":"14407_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21535","author":"T Ashikaga","year":"2010","unstructured":"Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010. https:\/\/doi.org\/10.1002\/jso.21535.","journal-title":"J Surg Oncol."},{"key":"14407_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.228","author":"AD Purushotham","year":"2005","unstructured":"Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005. https:\/\/doi.org\/10.1200\/JCO.2005.03.228.","journal-title":"J Clin Oncol."},{"key":"14407_CR7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9909-y","author":"R Crane-Okada","year":"2008","unstructured":"Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol. 2008. https:\/\/doi.org\/10.1245\/s10434-008-9909-y.","journal-title":"Ann Surg Oncol."},{"key":"14407_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.5784","author":"CM Rudenstam","year":"2006","unstructured":"Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10\u201393. J Clin Oncol. 2006. https:\/\/doi.org\/10.1200\/JCO.2005.01.5784.","journal-title":"J Clin Oncol."},{"key":"14407_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2615","author":"KS Hughes","year":"2013","unstructured":"Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013. https:\/\/doi.org\/10.1200\/JCO.2012.45.2615.","journal-title":"J Clin Oncol."},{"key":"14407_CR10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1217-7","author":"G Martelli","year":"2011","unstructured":"Martelli G, Miceli R, Daidone MG, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011. https:\/\/doi.org\/10.1245\/s10434-010-1217-7.","journal-title":"Ann Surg Oncol."},{"key":"14407_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2015.0647","author":"A Chung","year":"2015","unstructured":"Chung A, Gangi A, Amersi F, Zhang X, Giuliano A. Not performing a sentinel node biopsy for older patients with early-stage invasive breast cancer. JAMA Surg. 2015. https:\/\/doi.org\/10.1001\/jamasurg.2015.0647.","journal-title":"JAMA Surg"},{"key":"14407_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6322","author":"N Carleton","year":"2021","unstructured":"Carleton N, Zou J, Fang Y, et al. Outcomes after sentinel lymph node biopsy and radiotherapy in older women with early-stage, estrogen receptor-positive breast cancer. JAMA Netw Open. 2021. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.6322.","journal-title":"JAMA Netw Open."},{"key":"14407_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11079","author":"F Magnoni","year":"2019","unstructured":"Magnoni F, Massari G, Santomauro G, et al. Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. Br J Surg. 2019. https:\/\/doi.org\/10.1002\/bjs.11079.","journal-title":"Br J Surg."},{"key":"14407_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med."},{"key":"14407_CR15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-2-199401150-00002","author":"WA Satariano","year":"1994","unstructured":"Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994. https:\/\/doi.org\/10.7326\/0003-4819-120-2-199401150-00002.","journal-title":"Ann Intern Med."},{"key":"14407_CR16","doi-asserted-by":"crossref","unstructured":"Society of Surgical Oncology. Choosing Wisely: An Initiative of the ABIM Foundation. http:\/\/www.choosingwisely.org\/societies\/society-of-surgical-oncology\/ Published Jul 12, 2016. Accessed Feb 17, 2021.","DOI":"10.1016\/j.carage.2016.03.015"},{"key":"14407_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-558","author":"AK Falck","year":"2013","unstructured":"Falck AK, Fern\u00f6 M, Bendahl PO, Ryd\u00e9n L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases\u2013aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer. 2013. https:\/\/doi.org\/10.1186\/1471-2407-13-558.","journal-title":"BMC Cancer"},{"key":"14407_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr304","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ. Panel members. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011. https:\/\/doi.org\/10.1093\/annonc\/mdr304.","journal-title":"Ann Oncol"},{"key":"14407_CR19","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S18006","author":"Z Inic","year":"2014","unstructured":"Inic Z, Zegarac M, Inic M, et al. Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information. Clin Med Insights Oncol. 2014. https:\/\/doi.org\/10.4137\/CMO.S18006.","journal-title":"Clin Med Insights Oncol."},{"key":"14407_CR20","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2014.32.3.132","author":"HJ Han","year":"2014","unstructured":"Han HJ, Kim JR, Nam HR, Keum KC, Suh CO, Kim YB. Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients. Radiat Oncol J. 2014. https:\/\/doi.org\/10.3857\/roj.2014.32.3.132.","journal-title":"Radiat Oncol J."},{"key":"14407_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71221-5","author":"IH Kunkler","year":"2015","unstructured":"Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015. https:\/\/doi.org\/10.1016\/S1470-2045(14)71221-5.","journal-title":"Lancet Oncol."},{"key":"14407_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09273-1","author":"JG Jung","year":"2022","unstructured":"Jung JG, Ahn SH, Lee S, et al. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial. BMC Cancer. 2022. https:\/\/doi.org\/10.1186\/s12885-022-09273-1.","journal-title":"BMC Cancer"},{"key":"14407_CR23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9360-5","author":"JE Gervasoni Jr","year":"2007","unstructured":"Gervasoni JE Jr, Sbayi S, Cady B. Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol. 2007. https:\/\/doi.org\/10.1245\/s10434-007-9360-5.","journal-title":"Ann Surg Oncol."},{"key":"14407_CR24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5932-1","author":"JL Welsh","year":"2017","unstructured":"Welsh JL, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC. Predicting nodal positivity in women 70 years of age and older with hormone receptor-positive breast cancer to aid incorporation of a Society of Surgical Oncology Choosing Wisely guideline into clinical practice. Ann Surg Oncol. 2017. https:\/\/doi.org\/10.1245\/s10434-017-5932-1.","journal-title":"Ann Surg Oncol."},{"key":"14407_CR25","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i3.412","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014. https:\/\/doi.org\/10.5306\/wjco.v5.i3.412.","journal-title":"World J Clin Oncol."},{"key":"14407_CR26","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.n.026","author":"LA Carey","year":"2010","unstructured":"Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000\u20132010. Clin Breast Canc. 2010. https:\/\/doi.org\/10.3816\/CBC.2010.n.026.","journal-title":"Clin Breast Canc"},{"key":"14407_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001329","author":"JS Reis-Filho","year":"2010","unstructured":"Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: moving away from tumor philately. Sci Transl Med. 2010. https:\/\/doi.org\/10.1126\/scitranslmed.3001329.","journal-title":"Sci Transl Med"},{"key":"14407_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451\u201367.","journal-title":"Lancet."},{"key":"14407_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1274","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010. https:\/\/doi.org\/10.1200\/JCO.2009.23.1274.","journal-title":"J Clin Oncol."},{"key":"14407_CR30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11344","author":"ZH Li","year":"2016","unstructured":"Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.11344.","journal-title":"Oncotarget"},{"key":"14407_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp082","author":"MCU Cheang","year":"2009","unstructured":"Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Instit. 2009. https:\/\/doi.org\/10.1093\/jnci\/djp082.","journal-title":"J Natl Cancer Instit."},{"key":"14407_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt494","author":"M Gnant","year":"2014","unstructured":"Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014. https:\/\/doi.org\/10.1093\/annonc\/mdt494.","journal-title":"Ann Oncol."},{"key":"14407_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4618-z","author":"MG Rath","year":"2018","unstructured":"Rath MG, Uhlmann L, Fiedler M, et al. Oncotype DX\u00ae in breast cancer patients: clinical experience, outcome and follow-up-a case-control study. Arch Gynecol Obstet. 2018. https:\/\/doi.org\/10.1007\/s00404-017-4618-z.","journal-title":"Arch Gynecol Obstet."},{"key":"14407_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05686-3","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, Xu Y, Zhou Y, et al. Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age. Breast Canc Res Treat. 2020. https:\/\/doi.org\/10.1007\/s10549-020-05686-3.","journal-title":"Breast Canc Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14407-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T10:45:15Z","timestamp":1710931515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14407-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":34,"alternative-id":["14407"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14407-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kandace McGuire, MD: Mammotome Strategic Advisory Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}